Portal de investigación
Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
Fecha de publicación:
Fecha Ahead of Print:
Autores organización
Autores
- Ordóñez-Reyes C
- Garcia-Robledo JE
- Chamorro DF
- Mosquera A
- Sussmann L
- Ruiz-Patiño A
- Arrieta O
- Zatarain-Barrón L
- Russo A
- de Miguel-Perez D
- Rolfo C
Grupos de investigación
Resumen
Immunotherapy has redefined the treatment of cancer patients and it is constantly gen-erating new advances and approaches. Among the multiple options of immunotherapy, bispecific antibodies (bsAbs) represent a novel thoughtful approach. These drugs integrate the action of the immune system in a strategy to redirect the activation of innate and adaptive immunity toward specific antigens and specific tumor locations. Here we discussed some basic aspects of the design and function of bsAbs, their main challenges and the state-of-the-art of these molecules in the treatment of hematological and solid malignancies and future perspectives. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Datos de la publicación
- ISSN/ISSNe:
- 1999-4923, 1999-4923
- Tipo:
- Review
- Páginas:
- -
- Enlace a otro recurso:
- www.scopus.com
Pharmaceutics MDPI
Citas Recibidas en Web of Science: 12
Citas Recibidas en Scopus: 22
Documentos
- No hay documentos
Filiaciones
Keywords
- aldesleukin; antibody; asciminib; asparaginase; asparaginase macrogol; axitinib; azd 2936 inhibitor; azd 7789 inhibitor; B cell maturation antigen; B7 antigen; bafisontamab; bispecific antibody; blinatumomab; bortezomib; cadonilimab; capecitabine; CD123 antigen; CD137 ligand; CD19 antigen; CD20 antigen; CD28 antigen; CD3 antibody; CD33 antigen; CD47 antigen; CD69 antigen; CD86 antigen; cemiplimab; chemokine receptor CXCR3; cisplatin; cyclophosphamide; cytotoxic T lymphocyte antigen 4; daratumumab; daunorubicin; dexamethasone; doxorubicin; dual affinity retargeting antibody; dual affinity retargeting protein; elranatamab; eluvixtamab; emb 06 inhibitor; epidermal growth factor receptor; epithelial cell adhesion molecule; erfonrilimab; etoposide; Fc receptor; flotetuzumab; fludarabine phosphate; fluorouracil; folinic acid; fulvestrant; G protein coupled resector 5D; gemcitabine; gemtuzumab; gen 1047 inhibitor; glofitamab; hlx 301 inhibitor; ifosfamide; imatinib; interleukin 23 receptor; i
Proyectos asociados
EFECTO DEL EXTRACTO DE Trametes versicolor SOBRE EL FENOTIPO Y LA FUNCIÓN DE CÉLULAS DENDRÍTICAS HUMANAS CONDICIONADAS CON MEDIOS DE CÉLULAS DE CARCINOMA ORAL
Investigador Principal: ANDRES FELIPE CARDONA MENDOZA
PCI-2019-10805 . 2020
Citar la publicación
Ordóñez C,Garcia JE,Chamorro DF,Mosquera A,Sussmann L,Ruiz A,Arrieta O,Zatarain L,Rojas L,Russo A,de Miguel D,Rolfo C,Cardona AF. Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question. Pharmaceutics. 2022. 14(6):1243. IF:5,400. (1).